Computed tomography screening can detect lung cancer that is curable. However, some studies demonstrated that the risk for false-positives was about 50%. To make screening more efficient, we sought to create a forecasting model for individuals with different risks for lung cancer. Methods: We used multiple logistic regression analysis to identify independent predictors and to develop a prediction model. The pathological diagnoses in Guangdong Lung Cancer Institute were consecutively chosen as probands. All first-degree relatives of probands and their spouses were included as subjects. We divided the probands and their spouses into three subgroups according to the odds ratios (ORs), and the accuracy of lung cancer predictions for patients within the subgroups increased synchronously. Results: There were 633 proband pedigrees and 565 spouse pedigrees. Independent predictors of lung cancer included sex (OR, 1.6; 95% confidence interval [CI], 1.1-2.3), smoking history (light smoker: OR, 1.1; 95% CI, 0.7-1.8; heavy smoker: OR, 4.7; 95% CI, 3.1-7.1), lung disease history (OR, 5.3; 95% CI, 2.8-10.0), occupational exposure (OR, 1.6; 95% CI, 1.1-2.2), and number of affected individuals among first-degree relatives (n = 1: OR, 2.1; 95% CI, 1.3-3.4; n ≥ 2: OR, 4.7; 95% CI, 0.5-41.2). The accuracy of the pretest probability increased for those with higher ORs: low-OR subgroup, 68.3%; mid-OR subgroup, 84.0%; and high-OR subgroup, 91.9%. Conclusions: Our prediction rule is recommended for estimating the pretest probability of lung cancer, thereby facilitating early screening. Advances in multidetector computed tomography (CT) have made high-resolution volumetric imaging possible in a single breath hold at acceptable levels of radiation exposure, 3 allowing its use for certain lung-specific applications. The National Lung Screening Trial (NLST), a randomized trial of screening using low-dose CT compared with screening using chest radiography, suggested that screening using low-dose CT reduced mortality from lung cancer. 4 However, the false-positive rates were very high (approximately 95%) in both groups, probably because of chronic inflammation in the lungs associated with smoking. This suggests the need to carefully select patients for screening.
L ung cancer is an aggressive and heterogeneous disease. 1, 2 Advances in multidetector computed tomography (CT) have made high-resolution volumetric imaging possible in a single breath hold at acceptable levels of radiation exposure, 3 allowing its use for certain lung-specific applications. The National Lung Screening Trial (NLST), a randomized trial of screening using low-dose CT compared with screening using chest radiography, suggested that screening using low-dose CT reduced mortality from lung cancer. 4 However, the false-positive rates were very high (approximately 95%) in both groups, probably because of chronic inflammation in the lungs associated with smoking. This suggests the need to carefully select patients for screening.
From 1993 to 2005, the Early Lung Cancer Action Project (ELCAP) began a study on the early diagnosis of lung cancer in cigarette smokers, using annual screening with spiral CT. 5 Among the 302 participants with clinical stage I cancer, who underwent surgical resection within 1 month after diagnosis, the survival rate was 92% (prostate, lung, colorectal, and ovarian) (95% confidence interval [CI] , 88-95). However, for an individual in the PLCO cancer screening trial, the risk of a false-positive finding was approximately 50% or greater. 6 An important early step in the management of annual spiral CT screening is to estimate the clinical pretest probability of lung cancer. Intuitively, management should be more aggressive when the pretest probability is higher and more conservative when the pretest probability is lower. In this way, screening should be more efficient.
PATIENTS AND METHODS
This was a clinic-based study. All participants provided informed consent. The study protocol was approved by the Institutional Review Board.
Variables
We collected information about age, sex, race, stage, lung disease history, living environment, occupational exposure, smoking history, and the number of affected individuals as first-degree relatives. The same investigator interviewed the patients and their spouses using the unified genetic epidemiological survey. To reduce possible recall bias, we confirmed uncertain answers through the probands or their relatives by telephone. The reference group was made up of the probands' spouses.
The living environment was supplemented by detailed questions on cooking practices, fuel use, housing characteristics, and whether they lived in a polluted industrial zone. The selection of intensity was classified as never, light, and heavy. Analogously, the questions about occupational exposure included whether they usually had contact with dust, asbestos, radioactive material, and volatile chemicals for each work period of at least 1 year during the subject's lifetime. We determined the living environment or occupational exposure as positive if any of the selections was heavy.
Statistical Analyses
We used available data from this study to develop and internally validate a model of pretest probability. We developed the model using step-wise logistic regression with the diagnosis of lung cancer as the dependent variable and the following independent variables: age cohort (< 50/≥ 50 years), sex (female/male), lung disease history (never/ever), living environment (never/ever), occupational exposure (never/ ever), smoking history (never/< 20 pack-years/≥ 20 packyears), and number of affected individuals as first-degree relatives (0/1/≥ 2). Using backward selection, we arrived at a final parsimonious model by eliminating variables that were not statistically significant at a level of 0.05. All clinically plausible interactions were tested, but none were statistically significant; thus, they were not included in the final model. We report odds ratios (ORs) and 95% CIs for statistically significant predictors.
We used the Hosmer-Lemeshow goodness-of-fit statistic (p > 0.05) to evaluate model fit. 7, 8 We used the final model to calculate the estimated probability of lung cancer in each study participant. We then compared the predicted probability of lung cancer with the final diagnosis and constructed a receiver operating characteristic curve. To describe the accuracy of the model for identifying lung cancer in the study participants, we report the area under the curve (AUC) and its 95% CI. 9 We divided the study cohort into three subgroups according to their ORs compared with the general Chinese population: subgroup A-subjects with ORs of less than 5; subgroup B-subjects with ORs of at least 5, but less than 10; subgroup C-subjects with ORs of 10 and higher. Then, we analyzed the accuracy of lung cancer prediction for patients in each subgroup using logistic discriminant analysis. 10 We internally validated the model using a resampling or cross-validation procedure, enabling use of the full data set for model development. 11 To do this, we divided the study population into 10 equal groups by sampling randomly without replacement. For each group, we generated the predicted probability of metastasis using parameters that were estimated from a logistic regression model using data from the other nine groups. These 10 logistic regressions had identical specifications, and each used 90% of the data. We then calculated the AUC for the probabilities generated by the cross-validation.
RESULTS

Possible Influencing Factors
The characteristics of the 633 probands and 565 spouses are described in Table 1 . The mean age was 59.0 ± 11.3 years in the case arm and 57.7 ± 11.3 years in the control arm (Fig. 1 ). There were 426 patients with adenocarcinoma, 107 patients with squamous carcinoma, 54 patients with small-cell lung cancer, and 46 patients with other types of lung cancer. The statistically significant characteristics were sex, smoking history, lung disease history, and occupational exposure. Living environment was not significant at a level of 0.05, possibly because the couples lived together. However, we still introduced it into the model as an independent variable.
According to the number of affected individuals among the first-degree relatives of the probands and spouses, the pedigrees were divided into three groups: 0, 1, and 2 or more affected individuals ( Table 2) . As can be seen, apart from one subgroup with a small sample size in the control arm, the rest showed statistically significant differences. Therefore, we also introduced this factor into the model as an independent variable.
Independent Predictors of Lung Cancer in the Model
Familial aggregation of lung cancer has been reported in various populations since 1963. [12] [13] [14] [15] [16] Several studies [12] [13] [14] 17, 18 have shown that relatives of individuals with lung cancer are at an increased risk for the disease, even after adjusting for individual risk factors. These studies suggest that familial clustering of lung cancer may be influenced by not only shared environmental factors but also shared genes. Furthermore, some studies have indicated that early-onset lung cancer seems to be heritable and probably the result of a highly penetrant recessive gene or genes that predispose to tobacco carcinogens. [19] [20] [21] We took a stratified approach with age cohort (<50 versus ≥50 years; Table 3 ), and introduced this into the model as an independent variable.
We identified five independent predictors of lung cancer using multivariate logistic regression analysis ( Table 4) . The other potential predictors examined were not associated with a diagnosis of lung cancer and thus were not included in the final model. Men had a risk that was approximately 60% higher than that in women (OR, 1.60; 95% CI, 1.13-2.26). Light smokers seemed to have an increased risk, approximately 10% higher than never-smokers (OR, 1.11; 95% CI, 0.69-1.78), whereas heavy smokers had a risk of approximately five times that of never-smokers (OR, 4.72; 95% CI, 3.13-7.13). The likelihood of lung cancer increased more than fivefold for those with a lung disease history (OR, 5.33; 95% CI, 2.84-10.02) and by approximately 60% for those with an occupational exposure history (OR, 1.59; 95% CI, 1.13-2.23). Compared with the likelihood of lung cancer in subjects with no affected first-degree relative, the likelihood of lung cancer in those with one affected first-degree relative was approximately twofold (OR, 2.1; 95% CI, 1.28-3.43). The likelihood of lung cancer in those with two or more affected first-degree relatives was more than fourfold, although there was no statistical difference(OR, 4.67; 95% CI, 0.53-41.18). This might be because the sample size in the control group was just one.
Parsimonious Clinical Prediction Equation
The clinical prediction model is described by the following equations:
Probability of lung cancer = e 
where e is the base of the natural logarithm, smoke 1 is 1 for light smoker/0 for others, smoke 2 is 1 for heavy smoker/0 for others, lung disease is 1 for a lung disease history/0 for no history, occupational exposure is 1 for an occupational exposure history/0 for no history, N 1 is 1 for one affected individual among first-degree relatives, N 2 is 1 for two or more affected individuals among first-degree relatives.
When this model was used for prediction, we corrected the constant to estimate the pretest probability of lung cancer in the unconditional logistic regression model:
where n1 and n0 are the sample numbers in the case arm and control arm, respectively; q1 is 49.7/100,000, which is the a priori probability of lung cancer in the general Chinese population; 22 and q0 is equal to one minus q1. In the prediction model, the risk compared with that in the general Chinese population ranged from 0.41-fold to 121.31-fold (Table 5) . 23 Goodness-of-fit testing with the likelihood ratio and Hosmer-Lemeshow tests showed that the model accounted for the outcome better than chance alone (p < 0.01) and that the predicted likelihood of the outcome was similar to the observed likelihood (p = 0.62). A correlation matrix of parameter estimates revealed little evidence of multicollinearity.
The accuracy of the model was good, with an AUC of 0.75 (95% CI, 0.72-0.78). The predicted probabilities generated with the cross-validation procedure showed a similar AUC (0.71; 95% CI, 0.68-0.74). Using logistic discriminant analysis, the accuracy of the pretest probability was 68.3% in subgroup A, 84.0% in subgroup B, and 91.9% in subgroup C.
DISCUSSION
In 2004, the Genetic Epidemiology of Lung Cancer Consortium conducted a genome-wide linkage analysis of 52 extended pedigrees, ascertained through probands with lung cancer who had several first-degree relatives with the same disease. The results localized a major susceptibility locus influencing lung cancer risk to 6q23-25. Furthermore, the relative increase in the estimated proportion of linked families in subsets of families with an increasing number of affected individuals suggested a decrease in heterogeneity in the more informative families. 24 Thus, we analyzed subgroups based on the number of affected individuals among the first-degree relatives of the probands and spouses (0, 1, and ≥2), and the number of affected individuals among first-degree relatives was included as an independent predictor of lung cancer in the final model. This suggests a genetic influence on the risk for lung cancer.
CT screening can detect early-stage lung cancer in a high proportion of subjects, but it is associated with a high rate of false-positive results. The false-positive rates were very high in the NLST (approximately 95%) and the PLCO cancer screening trial (≥ 50%). In the present study, we used available data to develop and internally validate a new model for estimating pretest probability that may help guide the selection of the high-risk group. We identified five independent predictors of lung cancer: sex, smoking history, lung disease history, occupational exposure, and number of affected individuals among first-degree relatives. Importantly, we developed a parsimonious clinical prediction equation that estimates patientspecific probability of lung cancer with very good accuracy and excellent calibration. In our model, the accuracy of the pretest probability was 68.3% in subgroup A, 84.0% in subgroup B, and 91.9% in subgroup C. If we select people with ORs of at least 5 for screening, the risk of a false-positive finding may be much lower than in the earlier studies.
The participants in the ELCAP trial were asymptomatic. 5 The participants in the PLCO cancer screening trial met the selection criterion of 55 to 74 years of age. 6 In the NLST trial, eligible participants were between 55 and 74 years of age at the time of randomization, had a history of cigarette smoking of at least 30 pack-years, and if a former smoker, had quit within the previous 15 years. 4 As in these earlier studies, smoking history played an important role in our model. However, our model also included sex, lung disease history, occupational exposure, and number of affected individuals among first-degree relatives as independent predictors of lung cancer. Unlike the PLCO and NLST trials, our study did not demonstrate that older people were at a higher risk than younger people, because age cohort was not included as an independent predictor of lung cancer in the final model. Although the rows were ordered by OR estimates, we could see the effect of an individual variable on the risk estimates. Lung cancer was more closely linked to those with higher ORs, so the accuracy of their pretest probability was higher than accuracy of probability in those with lower ORs. McMahon et al. 25 showed that annual screening of current and former smokers aged between 50 and 74 years costs $126,000 to $1,69,000 per quality-adjusted life-year gained ($/QALY) (minimum 20 pack-years of smoking) or $110,000 to $166,000/QALY (40 pack-year minimum), as compared with no screening and assuming background quit rates. Although beneficial, screening had a higher cost per QALY when the model included radiation-induced lung cancers. We showed that the accuracy of the pretest probability increased in those with higher ORs, which suggests that the effectiveness and cost-effectiveness of strategies for CT screening in lung cancer may depend critically on the pretest probability of lung cancer. Our prediction equation may be used to facilitate clinical decision making regarding the selection and interpretation of CT screening for lung cancer. The equation could also be incorporated into a formal decision analysis or costeffectiveness analysis.
Our study has several limitations. This study collected little information about the severity of living environment, occupational exposure, and lung disease history. Consequently, additional predictors of lung cancer remain unidentified. Our results require external validation in an independent cohort of patients and then it would be possible to collect more detailed information to improve the current model. This model was developed in Chinese people and may be particularly well suited for use in this patient population only. The applicability of the model to other populations is unknown. Although living environment was not included in the final model, it should be considered before making clinical decisions. Furthermore, because the accuracy of the model is likely to depend on the prevalence of lung cancer in the target population, it may not be well calibrated for use in populations with a lower or higher prevalence of lung cancer compared with that in our study population. However, we believe that the prevalence of lung cancer in our study population is fairly representative of other groups, as we strove to reduce selection bias by enrolling all probands consecutively in 1 year.
Despite the very good accuracy of the model, we emphasize that it is not intended to be used as a standalone test, but rather as a tool to help guide the selection and interpretation of subsequent diagnostic tests.
This model showed greater value in people at higher risk. We conclude that the pretest probability of lung cancer can be estimated using a parsimonious clinical prediction equation, which may facilitate clinical decision making.
